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IL-23 plays a pivotal role in the pathogenesis of 
experimental colitis in mice (Hue et al., 2006; 
Yen et al., 2006; Elson et al., 2007; Izcue et al., 
2008). Compartmentalization of the IL-23/IL-17 
pathway  has  been  observed  in  these  models 
with IL-23 being the key cytokine driving in-
testinal inflammation, whereas systemic disease 
is dependent on IL-12 (Uhlig et al., 2006).   
Results from human studies have converged with 
the identification in patients with inflamma-
tory bowel disease (IBD) of multiple suscepti-
bility single nucleotide polymorphisms in many 
genes encoding for proteins involved in the   
IL-23/IL-17 pathway, including IL23R, IL12B, 
STAT3, JAK2, and CCR6 (Duerr et al., 2006; 
Barrett et al., 2008; Fisher et al., 2008; Franke   
et al., 2008). In addition, Th17 signature cyto-
kines (Wilson et al., 2007) are elevated in the 
intestine and serum of patients with IBD, and 
Th17 cells with an activated phenotype are 
present in the colon and blood of patients with 
Crohn’s disease (CD; Fujino et al., 2003; Andoh 
et al., 2005; Di Sabatino et al., 2009; Kleinschek 
et al., 2009). IL-23 plays an important role in 
sustaining Th17 responses (Cua et al., 2003). In 
addition to its effects on T cells, Takatori et al. 
(2009) have shown that IL-23 also acts on in-
nate lymphoid cells (ILCs) to induce IL-17 and 
IL-22 production. These ILCs share a similar 
phenotype to lymphoid tissue inducer (LTi) 
cells, which are involved in the organogenesis 
of secondary lymphoid organs through TNF 
and lymphotoxin-–mediated induction of 
the  adhesion  molecules  ICAM-1, VCAM-1, 
and MAdCAM-1 on mesenchymal cells (Mebius 
et al., 1997; Cupedo et al., 2004; Eberl et al., 
2004). LTi and related ILC populations are 
both dependent on the transcription factor 
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Results of experimental and genetic studies have highlighted the role of the IL-23/IL-17 
axis in the pathogenesis of inflammatory bowel disease (IBD). IL-23–driven inflammation 
has been primarily linked to Th17 cells; however, we have recently identified a novel popula-
tion of innate lymphoid cells (ILCs) in mice that produces IL-17, IL-22, and IFN- in re-
sponse to IL-23 and mediates innate colitis. The relevance of ILC populations in human 
health and disease is currently poorly understood. In this study, we have analyzed the role of 
IL-23–responsive ILCs in the human intestine in control and IBD patients. Our results show 
increased expression of the Th17-associated cytokine genes IL17A and IL17F among intesti-
nal CD3 cells in IBD. IL17A and IL17F expression is restricted to CD56 ILCs, whereas IL-23 
induces IL22 and IL26 in the CD56+ ILC compartment. Furthermore, we observed a signifi-
cant and selective increase in CD127+CD56 ILCs in the inflamed intestine in Crohn’s disease 
(CD) patients but not in ulcerative colitis patients. These results indicate that IL-23– 
responsive ILCs are present in the human intestine and that intestinal inflammation in CD is 
associated with the selective accumulation of a phenotypically distinct ILC population 
characterized by inflammatory cytokine expression. ILCs may contribute to intestinal inflam-
mation through cytokine production, lymphocyte recruitment, and organization of the 
inflammatory tissue and may represent a novel tissue-specific target for subtypes of IBD.
© 2011 Geremia et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months it 
is available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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ILCs may contribute to intestinal inflammation through the 
production of IL-17 and the recruitment of other inflamma-
tory cells and therefore may represent a novel tissue-specific 
therapeutic target for patients with IBD.
RESULTS AND DISCUSSION
Th17 signature genes are expressed in intestinal  
non-T cells in the absence of intestinal inflammation  
and are overexpressed in IBD
In this study, we aimed to analyze the contribution of adap-
tive and innate sources of Th17 signature cytokines to chronic 
intestinal inflammation in patients with IBD. We confirmed 
the overexpression of Th17 signature cytokine genes in the 
inflamed intestinal mucosa in our cohort of patients with 
IBD, either ulcerative colitis (UC) or CD, compared with the 
nonaffected colon of patients undergoing colectomy for 
colorectal cancer as noninflammatory controls (Fig. 1 A). To 
evaluate the contribution of innate and adaptive sources of 
Th17 signature cytokines in the human systemic and intesti-
nal immune response in the absence and presence of IBD, we 
compared T cell and non-T cell expression of Th17 genes in 
the peripheral blood (PB) versus the lamina propria (LP) of 
IBD patients and controls (Fig. 1, B and C). We found prefer-
ential expression of IL22, IL17A, IL17F, and IL26 in CD3+ 
RAR-related orphan receptor C (RORC), which is also re-
quired for Th17 cell development. Whereas LTi cells are 
active in the fetus, IL-22–producing ILC populations are 
thought to provide innate antimicrobial defense in the adult 
(Satoh-Takayama et al., 2008; Luci et al., 2009; Sanos et al., 
2009). Recently, we have described an IL-23–responsive ILC 
population that mediates innate colitis through an IL-17– and 
IFN-–dependent mechanism, indicating an important func-
tional role for ILCs in the intestinal inflammatory response 
(Buonocore et al., 2010).
IL-23–responsive ILC populations have also been identi-
fied in human mucosa-associated lymphoid tissue, such as   
intestinal Peyer’s patches and tonsils. Cella et al. (2009) de-
scribed CD3CD56+NKp44+ cells, termed NK22 cells, that 
produce IL-22 but not IL-17 in response to IL-23. Like Th17 
cells, NK22 cells also express the transcription factor RORC. 
Although originally thought to represent a subset of NK cells, 
recent studies suggest that NK22 cells are developmentally 
and functionally related to LTi cells (Crellin et al., 2010;   
Satoh-Takayama et al., 2010). The role of human innate lym-
phoid  sources  of  IL-17  and  IL-22  in  the  pathogenesis  of 
immunological disorders has not been investigated. In this 
study, we describe the accumulation of IL-23–responsive 
ILCs in the inflamed intestine of patients with CD. Human 
Figure 1.  Th17 signature genes are expressed in intestinal CD3 cells and overexpressed in IBD. (A) Relative messenger RNA (mRNA) expression 
of Th17 signature cytokines in intestinal tissue homogenates from control, UC, and CD patients. (B and C) mRNA expression of Th17-related genes in 
CD3+ cells (B) and CD3 cells (C) isolated from blood and intestine of control (open circles) and IBD (closed circles) patients. In some experiments, B cells 
have been excluded (CD3CD19 cells). (A–C) The horizontal bars represent the mean of each of the groups. *, P < 0.05; **, P < 0.01; ***, P < 0.001.JEM Vol. 208, No. 6  1129
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Compartmentalization of Th17 gene expression was not   
restricted to T cells as we also found increased expression of 
IL22, IL17F, and IL26 in LP CD3 cells with nondetectable 
or very low expression among PB CD3 cells (Fig. 1 C) in both 
cells isolated from the intestine compared with the blood of both 
control and IBD patients (Fig. 1 B). In line with these results, 
Kobayashi et al. (2008) described higher expression of IL-17   
in LP CD4+ cells compared with the PB CD4+ population. 
Figure 2.  ILCs are a source of IL-17 in IBD. (A) mRNA expression of IL22, IL17A, IL17F, and IL26 in CD3 cells from control (open bars; n = 9 for IL22, 
IL17A, and IL17F and n = 7 for IL26) and IBD colon (closed bars; n = 4) after overnight culture in complete media with no addition (NA) and in the pres-
ence of 10 ng/ml IL-23. In some experiments, B cells have been excluded (CD3CD19 cells). **, P = 0.006. (B) mRNA expression of IL22, IL26, IL17A, and 
IL17F in LinCD45+CD56+ and LinCD45+CD56 cells from the ileum (n = 4) and colon (n = 4) of patients with CD after overnight stimulation in complete 
media with no addition (NA) and in the presence of 10 ng/ml IL-23. *, P = 0.029. (A and B) Mean ± standard error of the mean is represented. (C) Intracel-
lular staining for IL-17A and IFN- after PMA/ionomycin stimulation in LPMCs isolated from the ileum of a patient with CD (representative of two experi-
ments). LPMCs were gated on the lymphocytic gate (FSC/SSC), were CD3CD19CD14, CD16, CD45+, and costained with CD56 and CD127.1130 Innate lymphoid cells in IBD | Geremia et al.
IBD and control individuals. IL17A expression was also in-
creased in LP CD3 cells compared with PB CD3 in IBD 
patients. This increase was specific to intestinal inflammation 
because no significant difference was observed in noninflamed 
controls. Other Th17 genes such as IL21, IL23R, RORC, and 
aryl hydrocarbon receptor (AHR) were also expressed in both the 
intestinal T and non-T cell compartments, with very low or 
nondetectable expression in blood leukocytes (Fig. S1, A and B). 
These results confirm our hypothesis of a specific role for the 
IL-23 axis in the intestinal immune response and show that 
both T and non-T cells expressing Th17-related genes are 
present in the human intestine.
Interestingly, we found no significant differences between 
patients and controls in expression of Th17 genes in LP CD3+ 
cells (Fig. 1 B and Fig. S1 A), although absolute numbers of 
intestinal Th17 cells are increased in IBD, as suggested by 
Kleinschek et al. (2009). Strikingly, significantly higher expres-
sion of IL17A and IL17F was observed in LP CD3 cells iso-
lated from patients with IBD (Fig. 1 C) compared with 
controls. No significant difference was observed for IL22, IL26, 
RORC, AHR, and IL23R expression (Fig. 1 C and Fig. S1 B). 
IL21 expression was very low or undetectable in most PB and 
LP CD3 cells from IBD patients (Fig. S1 B). These findings 
suggest that innate sources of IL-17A and IL-17F might con-
tribute to intestinal inflammation in IBD.
ILCs are a source of IL-17 and accumulate in the intestine 
of patients with CD
To determine whether intestinal non-T cells are responsive to 
IL-23 and whether the innate response is altered in IBD, 
sorted LP CD3 cells from patients and controls 
were cultured overnight with or without IL-23, 
and Th17 gene expression was evaluated (Fig. 2 A). 
IL22 was induced by IL-23 stimulation in non-
T cells isolated from control colon, confirming 
the presence of IL-23–responsive innate cells in 
the human intestine. Induction of IL26 was not 
observed  after  IL-23  stimulation  in  LP  CD3 
cells from either controls or IBD patients. How-
ever, IL26 transcripts were very low in some cul-
tures, leading to a large variation in expression 
levels. Interestingly, IL17A in LP CD3 cells after 
IL-23 stimulation was significantly higher in cells 
isolated from patients with IBD compared with 
controls. All together, these data suggest that an 
IL-23–dependent source of IL-17 is present in the CD3 
compartment in the inflamed colon of patients with IBD but 
not in controls.
In humans, CD3CD127+ ILCs can be further subdi-
vided based on expression of the NK marker CD56 (Crellin 
et al., 2010). Both populations can be isolated from human 
adult tonsils and share the expression of NKp44, NKp46, 
CD161, c-Kit, and RORC. In vitro expanded CD127+CD56 
and CD127+CD56+ cells showed a similar cytokine profile, 
including production of IL-17, IL-22, and IFN-. In vitro 
analysis suggests a precursor-product relationship with CD56 
expression induced upon activation. However, the relative 
distribution and function of these ILC populations in the human 
intestine in health and disease have not been examined.
To  further  characterize  the  intestinal  IL-23–responsive 
non-T cell source of Th17 cytokines in the inflamed intestine 
of patients with IBD, we sorted CD3CD19CD14CD1
6(Lin) CD45+CD56+ cells and LinCD45+CD56 cells 
from the ileum and colon of patients with CD and cultured 
them with IL-23. IL22 and IL26 were induced by IL-23 in 
the CD56+ population. In contrast, IL17A and IL17F were 
preferentially expressed in the LinCD45+CD56 popula-
tion analyzed directly ex vivo, and levels were not increased 
upon addition of IL-23 (Fig. 2 B). Expression of IFN was 
detected among ileal as well as colonic LinCD45+CD56+ 
and LinCD45+CD56 cells from patients with CD (Fig. S2).   
Further analysis of the phenotype of IL-17A– and IFN-– 
producing cells in the Lin compartment by intracellu-
lar FACS staining showed that these cells were primarily 
CD127+CD56 (77% and 90%, respectively; Fig. 2 C). Analysis 
Figure 3.  CD56 ILCs accumulate in the intestine in 
CD. (A) Representative staining of CD127+CD56 and 
CD127+CD56+ ILCs from control and CD intestine. LPMCs were 
gated on the lymphocytic gate in the FSC/SSC plot, the Lin 
and CD45+ population. (B and C) Percentage of CD127+CD56 
(B) and CD127+CD56+ ILCs (C) in the LinCD45+ population, 
using the gates shown in A, in the colon of control, CD, and 
UC patients and in the ileum of control and CD patients.  
(B and C) The horizontal bars represent the mean of each of 
the groups. *, P = 0.048; **, P = 0.004.JEM Vol. 208, No. 6  1131
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severe disease, chronically active disease, or complications of disease. Blood 
samples and gut specimens from macroscopically healthy areas were collected 
from colorectal cancer patients as noninflammatory controls. Biopsies were 
collected from inflamed areas of the colon and small bowel of patients with 
IBD, undergoing endoscopy for assessment of disease activity, extension   
or surveillance, and the noninflamed intestine of healthy subjects. Ethical   
approval was obtained from the Oxfordshire Research Ethics Committee 
(reference number 07/Q1605/35), and informed written consent was given 
by all study participants.
Isolation  of  cells. LP mononuclear cells (LPMCs) were isolated using   
a modified version of the protocol described by Bull and Bookman (1977). 
In brief, the mucosa was dissected, cut in pieces <25 mm2, and washed in   
1 mM DTT solution at room temperature for 15 min to remove adherent 
mucus. Specimens were washed three times in 0.75 mM EDTA solution at 
37°C for 45 min to detach the epithelial crypts and then digested overnight 
in 0.1 mg/ml collagenase D solution (Roche). Cells were then centrifuged 
for 30 min in a Percoll gradient and collected at the 40–60% interface. All 
solutions used were supplemented with antibiotics (penicillin/streptomycin, 
40 µg/ml gentamicin, and 0.025 µg/ml Amphotericin B).
PB was diluted in an equal volume of PBS and centrifuged over a Ficoll-
Hypaque layer at 2,000 rpm. Cells were collected at the Ficoll–dilute plasma 
interface. LPMCs were isolated from biopsies (up to 10 per patient) using a 
combined mechanical (GentleMACS; Miltenyi Biotech) and enzymatic di-
gestion process.
Cell sorting. CD3+ and CD3 cells were sorted either by magnetic cell 
sorting with positive selection of CD3+ (CD3 Micro Beads; Miltenyi 
Biotech) or by FACS using a MoFlow (Dako). CD3, CD3CD19, 
LinCD45+CD56+, and LinCD45+CD56 cells were FACS sorted. The 
following antibodies were used: anti-CD3, anti-CD19, anti-CD56 (BD), 
anti-CD14, anti-CD16 (eBioscience), and anti-CD45 (BioLegend).
Cultures. Cells were cultured in RPMI with 10% FCS, antibiotics, and   
l-glutamine with or without recombinant human IL-23 (R&D Systems) at 
10 ng/ml concentration.
Quantitative PCR. RNA was isolated from cells using the RNeasy Mini 
kit (QIAGEN) and cDNA synthesized using Superscript III and oligo (dT) 
primers  (Invitrogen).  Quantitative  PCR  was  performed  with  ACTB-, 
IL17A-, IL17F-, IL22-, IL21-, IFN–, IL23R-, RORC-, and AHR-
specific primers (QuantiTect Primer Assays; QIAGEN) and Platinum SYBR 
green qPCR super mix (Invitrogen). TaqMan Gene Expression Assays for 
ACTB and IL26 were also used in some experiments (Applied Biosystems). 
cDNA samples were assayed in triplicate using the Chromo4 detection sys-
tem (GMI), and gene expression levels for each individual sample were nor-
malized  to  -actin.  Mean  relative  gene  expression  was  determined  and 
expressed as 2CT (CT = CTgene  CT-actin) × 10,000.
FACS staining. Cells were preincubated in 2% normal rat serum. The fol-
lowing antibodies were used for flow cytometry: anti-CD3, anti-CD19, 
anti-CD56  (BD),  anti-CD14,  anti-CD16,  anti-CD127,  anti–IL-17,  anti–
IFN-, anti-NKp44, anti-CCR6 (eBioscience), and anti-CD45 (BioLegend). 
For the intracellular staining, cells were stimulated with PMA and iono-
mycin in the presence of brefeldin A for 4 h and fixed/permeabilized 
(eBioscience). Analysis was performed using FlowJo software (Tree Star), 
and gates were set using relevant IgG isotype controls.
Statistics.  The  nonparametric,  two-tailed  Mann-Whitney  test  was  per-
formed in Prism software (GraphPad Software) in all cases. Mean ± standard 
error of the mean is represented on bar charts.
Online supplemental material. Fig. S1 shows that Th17 signature genes 
are expressed in intestinal CD3 cells and overexpressed in IBD. Fig. S2 
shows that IFN- is expressed in both intestinal LinCD45+CD56+ and 
of the frequency of intestinal LinCD45+CD127+CD56 cells 
and LinCD45+CD127+CD56+ (termed CD56 and CD56+ 
ILCs) in patients with CD, UC, and controls showed that 
although both populations were present at similar frequen-
cies in the uninflamed colon and ileum of control individ-
uals, there was a marked increase specifically in CD56 ILCs 
in the inflamed ileum and colon of CD patients. Interest-
ingly, no difference in the frequency of CD56 and CD56+ 
ILCs was observed in the colon of UC patients versus con-
trols, indicating that accumulation of CD56 ILCs might be 
a specific feature of CD (Fig. 3, A–C). Consistent with low 
IL22 expression, only a small percentage of CD56 ILCs that 
accumulated in CD expressed NKp44, suggesting that they 
represent a distinct population from IL-22–producing NK22 
cells, which expressed NKp44 and represented a quarter of 
CD56+ ILCs (Fig. S3 A). Both intestinal CD56 and CD56+ 
ILCs also expressed the chemokine receptor CCR6 (Fig. S3 B). 
It has been reported that CCL20 and -defensins, which are 
known CCR6 ligands, are both increased in the inflamed in-
testine of patients with IBD (Wehkamp et al., 2002; Kwon   
et al., 2003; Kaser et al., 2004). These results raise the possibil-
ity that a CCR6-mediated mechanism might be responsible 
for the recruitment of ILCs to the intestine in IBD.
In this study, an IL-23–dependent innate lymphoid source 
of IL-17A and IL-17F, which shares features of human LTi 
cells, has been identified in the intestine of patients with CD. 
The  differential  accumulation  of  IL-17A–  and  IL-17F– 
producing ILCs in the inflamed CD intestine is very similar to 
the accumulation of IL-17A–secreting ILCs that mediate in-
nate colitis in mice (Buonocore et al., 2010). Further under-
standing  of  the  factors  that  selectively  promote  IL-17–producing 
ILCs  at  the  expense  of  tissue-protective  IL-22–producing 
populations during intestinal inflammation may provide novel 
insights into immune pathology in the intestine. It is notable 
that increases in NKp44NKp46+CD56+CD3 cells capable 
of secreting IFN-g in response to IL-23 have been observed 
in CD patients, emphasizing a more pathogenic phenotype 
amongst ILC populations (Takayama et al., 2010). These results 
also raise important questions about the developmental relation-
ship between CD56 and CD56+ ILC populations in vivo.
CD56 ILCs may contribute to chronic intestinal inflam-
mation not only through the production of inflammatory   
cytokines such as IL-17A and IL-17F but potentially through 
induction of adhesion molecules and recruitment of other 
lymphocytes. Indeed, increased numbers of isolated lymphoid 
follicles are typically found in the colon of patients with IBD. 
This study opens the way to further work on the functional 
role of distinct ILC populations in intestinal inflammation 
and identifies a potential tissue-specific target for the treat-
ment of patients with IBD.
MATERIALS AND METHODS
Study subjects. All patients and controls were recruited from the gastro-
enterology unit and the colorectal surgery department at the John Radcliffe 
Hospital in Oxford. The diagnosis of IBD was confirmed by established clini-
cal, radiological, endoscopic, and histological criteria. Blood samples and gut 
specimens were obtained from patients with IBD undergoing surgery for   1132 Innate lymphoid cells in IBD | Geremia et al.
LinCD45+CD56 cells. Fig. S3 shows phenotyping of intestinal CD56 
and CD56+ ILCs. Online supplemental material is available at http://www 
.jem.org/cgi/content/full/jem.20101712/DC1.
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